NEW
YORK, May 16, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a
clinical stage biopharmaceutical company developing novel products
to treat brain health disorders, announced today that the
registration statement on Form S-3, filed on May 4, 2022, was declared effective by the U.S.
Securities and Exchange Commission, which includes a prospectus for
an at-the-market equity offering under which the Company may offer
and sell its Subordinate Voting Shares or common shares
re-designated from the Company's Subordinate Voting Shares
(collectively, the "shares") for up to $100,000,000 in aggregate sales proceeds in "at
the market" transactions (the "ATM Program'').
![Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed)) Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))](https://mma.prnewswire.com/media/996320/Mindmed_Logo.jpg)
Distributions of the shares under the ATM Program will be made
pursuant to the terms of an equity offering sales agreement entered
with agents Cantor Fitzgerald & Co., and Oppenheimer & Co.
Inc. The volume and timing of distributions under the ATM Program,
if any, will be determined in the Company's sole discretion. The
shares will be distributed at the market prices prevailing at the
time of each sale and, as a result, prices may vary between
purchasers and during the period of the ATM Program. The ATM
Program will be effective until the earlier of the issuance and
sale of all of the shares issuable pursuant to the ATM Program and
the end of the effective period of the Registration Statement on
Form S-3 (File No. 333-264648), unless terminated prior to such
date by the Company or the agents in accordance with the terms of
the equity offering sales agreement. No offering or sale of shares
under the ATM Program shall occur in Canada or to a person resident in Canada.
The securities described above are being offered by the Company
pursuant to a shelf registration statement on Form S-3 previously
filed with the Securities and Exchange Commission (the "SEC"),
which the SEC declared effective on May 16,
2022. Copies of the prospectus relating to the ATM Program
may be obtained from Cantor Fitzgerald & Co., Attn: Capital
Markets, 499 Park Avenue, 4th floor, New
York, NY 10022; email: prospectus@cantor.com, or Oppenheimer
& Co. Inc., 85 Broad Street, 26th Floor, New York, NY 10004, Attn: Syndicate Prospectus
Department, telephone: (212) 667-8055 or email:
EquityProspectus@opco.com, or by accessing the SEC's website,
www.sec.gov, or on SEDAR at www.sedar.com.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy the shares, nor shall there be any
sale of shares in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, with a particular
focus on psychiatry, addiction, pain and neurology. The Company is
developing a pipeline of innovative drug candidates, with and
without acute perceptual effects, targeting the serotonin, dopamine
and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and is therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding potential
sales of shares pursuant to the Company's ATM Program. There are
numerous risks and uncertainties that could cause the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information, such as those risks discussed or
referred to herein and the risks described in the Company's Annual
Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on
Form 10-Q for the period ended March 31,
2022 under headings such as "Special Note Regarding
Forward-Looking Statements," and "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and other filings and furnishings made by the Company
with the securities regulatory authorities in all provinces and
territories of Canada which are
available under the Company's profile on SEDAR at
www.sedar.com and with the U.S. Securities and Exchange
Commission on EDGAR at www.sec.gov. Except as required by law,
the Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
SOURCE Mind Medicine (MindMed) Inc.